… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … with LCA10 and preclinical data for ProQR’s Axiomer ® RNA-editing technology. Abstract titles: ○ Proof-of-concept …
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … November 20 at 1:20-2:00 p.m. GMT Presentation at the 1 st RNAEditing Summit During the 1 st RNAEditing Summit to be held …
… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … advisory board. "Dr. Yu is a pioneer of targeted RNAediting to correct protein translation defects caused by …